Atorvastatin
Treatment for Ischemic Heart Disease
Typical Dosage: 10-80mg daily
Effectiveness
90%
Safety Score
65%
Clinical Trials
186
Participants
200K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
10-80mg daily
Time to Effect
3-6 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
20(Treat 20 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$150
Side Effect Mgmt:$20
Total Annual:$200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$10,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$250
Comparison vs No treatment
Cost Difference
+$200/year
More expensive
QALY Difference
+1.50 QALYs
Better outcomes
Dominance
No dominance
Atorvastatin Outcomes
for Ischemic Heart Disease
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+80%
Common Side Effects
Myalgia
+5%
Liver enzyme elevation
+2%
Headache
+3%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
12 completed trials for Atorvastatin in Ischemic Heart Disease
Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
NCT00701220COMPLETEDPHASE4
9 participants
INTERVENTIONAL
Columbus, United States
Started: Apr 1, 2007
Statin Therapy In Atrial Refractoriness and Reperfusion Injury
NCT01780740COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Oxford, United Kingdom
Started: Jan 1, 2012
Statin Drugs to Prevent Complications During Surgery
NCT00967434COMPLETEDNA
60 participants
INTERVENTIONAL
Ottawa, Canada
Started: Dec 1, 2007
Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin
NCT00973986COMPLETEDPHASE1
20 participants
INTERVENTIONAL
Guangzhou, China
Started: Jun 1, 2009
Atorvastatin Effect on Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention
NCT04375787COMPLETEDPHASE4
200 participants
INTERVENTIONAL
Asyut, Egypt
Started: Mar 15, 2020
Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease
NCT01946815COMPLETEDPHASE3
119 participants
INTERVENTIONAL
Ulsan, South Korea +3 more
Started: Sep 1, 2013
Pilot Study of Atorvastatin for Orthopedic Surgery Patients
NCT02197065COMPLETEDPHASE2
20 participants
INTERVENTIONAL
New York, United States +1 more
Started: Sep 1, 2014
COmparison and Modification in Neointimal Pattern Assessed by Optical Coherence Tomography With High Versus Moderate Efficacy Statin Treatment After Drug Eluting Stent Implantation: COMPASS Trial
NCT02155530COMPLETEDNA
30 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jun 1, 2014
Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study
NCT00469326COMPLETEDPHASE3
200 participants
INTERVENTIONAL
Prague, Czechia
Started: Apr 1, 2005
Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel
NCT00405717COMPLETEDPHASE4
1.3K participants
INTERVENTIONAL
Shenyang, China
Started: Feb 1, 2006
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
NCT00134173COMPLETEDPHASE3
1.1K participants
INTERVENTIONAL
Birmingham, United States +145 more
Started: Oct 1, 2003
Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
NCT00993915COMPLETED
687 participants
OBSERVATIONAL
Started: Apr 1, 2010
Showing 20 of 187 total trials